Given the scalability of DNA manufacturing and ease of DNA delivery relative to
conventional recombinant protein
monoclonal antibody therapies, the DMAb platform has potential to greatly expand the market for
monoclonal antibody prophylaxis /
therapy against challenging infectious disease targets.